Table 1.

Baseline characteristics by duration of statin drug use (CMHS 2002-2004)

CharacteristicStudy population, n = 69,047 (%)Duration of statin use*
0-100 d (n = 46,144)101 d to <5 y (n = 18,133)≥5 y (n = 4,770)
Age
    <5010,697 (15.5)19.09.44.2
    50-5929,421 (42.6)45.738.229.5
    60-6928,082 (40.7)34.350.863.9
    ≥70847 (1.2)1.01.62.4
Race
    Non-Hispanic White43,138 (62.5)63.559.663.6
    Black/African American5,076 (7.4)6.98.47.7
    Hispanic9,209 (13.3)13.413.810.9
    Asian5,370 (7.8)7.97.77.3
    Other6,254 (9.1)8.410.410.4
Family history of prostate cancer
    No55,746 (80.7)80.780.980.7
    Yes8,546 (12.4)12.811.711.4
    Missing4,755 (6.9)6.67.47.9
Membership, median (y)*69,047 (8.8)8.78.89.4
KP California region
    Southern31,498 (45.6)44.946.947.7
    Northern37,549 (54.4)55.153.152.4
Education
    Less than high school3,939 (5.7)5.56.45.4
    High school graduate8,080 (11.7)11.013.113.8
    Some college23,679 (34.3)33.436.733.9
    College graduate33,071 (47.9)49.843.446.6
    Missing278 (0.4)0.40.40.3
Body mass index
    <18.5 kg/m2413 (0.6)0.60.60.5
    18.5 to <25 kg/m217,726 (25.7)28.520.119.5
    25 to <30 kg/m231,893 (46.2)46.345.846.9
    ≥30 kg/m217,913 (25.9)23.031.931.5
    Missing1,102 (1.6)1.61.61.6
High-fat diet
    No35,495 (51.4)50.851.656.6
    Yes33,552 (48.6)49.248.443.4
Regular NSAID use
    No29,378 (42.6)49.531.019.2
    Yes36,114 (52.3)45.363.776.9
    Missing3,555 (5.2)5.25.33.9
Other antihyperlipidemic drug dispensing§
    Never63,554 (92.0)97.485.764.4
    Ever5,493 (8.0)2.614.335.6
History of PSA testing
    No17,337 (25.1)29.517.312.5
    Yes51,710 (74.9)70.582.787.6
History of cardiovascular disease
    No36,271 (52.5)62.335.821.7
    Yes32,776 (47.5)37.764.278.3
History of hyperlipidemia
    No40,955 (59.3)75.231.112.6
    Yes28,092 (40.7)24.868.987.4
History of diabetes
    No59,098 (85.6)93.969.167.9
    Yes9,949 (14.4)6.130.932.1
History of BPH
    No52,840 (76.5)78.273.970.2
    Yes13,533 (19.6)18.221.724.9
    Missing2,674 (3.9)3.64.45.0
  • NOTE: Baseline is the date of a completed CMHS questionnaire.

  • * Duration of use defined as the total days dispensed of statin drug(s) from the first recorded dispensing until the end of follow-up. All frequencies expressed as percentages, except for membership, which is median years(y) of Kaiser Permanente membership from 1980 until baseline.

  • High-fat diet defined as having >35% of total daily calories come from fat calories.

  • Regular NSAID use defined as those who reported taking NSAIDs ≥3 to 4 d per week within the 3 mo prior to baseline and/or had >100 d total prescription NSAIDs dispensed from a Kaiser pharmacy prior to baseline.

  • § Other antihyperlipidemic drugs include fibric acid derivatives, bile acid resins, niacin/nicotinic acid, ezetimibe, and miscellaneous (probucol, docosahexanoic acid).

  • History of at least one medical record of a PSA test within 5 y prior to baseline.